報價延遲最少15分鐘:2026/07/15 08:29 EDT
盤前時段
|
||||
|
659.8327 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
656.12
|
|
|
| 價值評估 |
|
盈利(現時/預測)
40.96/47.74
|
|
企業價值
72.22B
|
| 資產負債 |
|
每股賬面淨值
299.73
|
| 現金流量 |
|
現金流量率
0.07
|
| 損益表 |
|
收益
14.34B
|
|
每股收益
124.93
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners. |
